SUO 2017: Targeted Early Detection In Men At High Genetic Risk For Prostate Cancer
Washington, DC (UroToday.com) Heritable mutations that predispose to prostate cancer are increasingly being recognized, and the NCCN Early Detection guidelines now include “family or personal history of BRCA1/2 mutations” as an important factor in the decision whether to perform prostate cancer screening.
SUO 2017: Papillary Urothelial Neoplasia of Low Malignant Potential (PUNLMP) Recurrence Rates
Washington, DC (UroToday.com) Dr. Neal Shore and colleagues presented their research on papillary urothelial neoplasia of low malignant potential (PUNLMP) recurrence rates. As of 2004, the World Health Organization (WHO) has endorsed PUNLMP as a uropathologic entity, stratifying WHO 1973 Grade 1, 2, and 3 tumors as PUNLMP, low grade, and high-grade disease, respectively. Some pathologists report a 1:1 exchange as G1: PUNLMP, G2: low-grade, G3: high-grade, whereas others propose a sliding comparison designating G1 to either PUNLMP or low grade, and G2 to either low-grade or high-grade tumors. Despite PUNLMP’s seemingly innocuous clinical course, the authors note that many are still uncertain regarding its low risk of recurrence. The objective of this study was to review data from two phase III non-muscle invasive bladder cancer (NMIBC) trials with prospective central pathology to report PUNLMP incidence and 2-year recurrence rates and to assess the benefit of a single dose of an intravesical therapy.
SUO 2017: Survival Among Female Urethral Cancer Patients 2004-2013, A National Cancer Database Analysis
Washington, DC (UroToday.com) Introduction: Primary urethral cancers account for less than 1% of all GU cancers. Due to the rarity of this condition, The authors aimed to describe the practice patterns in the management of female urethral cancer in a contemporary cohort.
SUO 2017: Should Partial Nephrectomy Be Considered Elective In Stage 2 Chronic Kidney Disease? Propensity Score Matched Analysis Of Functional And Survival Outcomes After Radical And Partial Nephrectomy
Washington, DC (UroToday.com) Introduction: While partial nephrectomy (PN) is strongly indicated for patients with stage 3-4 chronic kidney disease [(CKD), eGFR<60 ml/min/1.73m2], higher GFRs are thought to be elective. The authors compared renal function and survival outcomes in patients with baseline stage II CKD who underwent PN or radical nephrectomy (RN).
SUO 2017: Benefits of Alvimopan in Men Undergoing Retroperitoneal Lymph Node Dissection
Washington, DC (UroToday.com) With an increasing emphasis on improving post-operative courses after major operations, the ERAS pathway has been enthusiastically taken up by the bladder cancer community. However, a key component of the ERAS pathway is the use of pre-operative alvimopan (Entereg), a mu-receptor opioid antagonist. Having demonstrated efficacy in GI surgery and the radical cystectomy literature at reducing hospital length of stay and postoperative morbidity, the authors from this study assessed its utility following RPLND for testicular cancer.
SUO 2017: Multiplex Partial Nephrectomy In A Solitary Kidney: The NCI Experience With Partial Nephrectomy For Three or More Tumors in Comparison To Standard Partial Nephrectomy In A Solitary Kidney
Washington, DC (UroToday.com) Introduction: Multiplex partial nephrectomy (MxPNx) is the excision of three or more tumors during the same procedure and has been shown to have distinct outcomes compared to standard partial nephrectomy (sPNx) for 1 or 2 tumors. Outcomes for MxPNx in the setting of a solitary kidney has not been previously reported.
SUO 2017: Quality Improvement Initiative for Patients with Muscle-Invasive Bladder Cancer
Washington, DC (UroToday.com) Dr. Milowsky and colleagues presented their research on a quality improvement (QI) initiative for patients with muscle-invasive bladder cancer (MIBC). Thought leaders in the field have called for QI initiatives in response to suboptimal care for patients with MIBC. As such, the objective of this study was to evaluate the impact of a QI program at two MIBC centres regarding quality-focused interventions on assessment, treatment, and patient-centered care processes.